55 companies making pharmaceutical companies will benefit from an incentive of Rs 15,000 crore given under the PLI scheme for the pharmaceuticals sector. In a release issued by the government, it has been said that the industry has strongly welcomed the government’s PLI scheme. Till 31 August 2021, 278 applications were received for incentives under the scheme. 55 applications were to be accepted under the scheme.
Many companies including Sun Pharma benefit
The companies that will get the benefit of this scheme include- Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Lupine Limited, (Lupin Limited) ) Mylan Laboratories Limited, Cadila Healthcare Limited, Cipla Limited, Amneal Pharmaceuticals Private Limited, Glenmark (Glenmark Pharmaceuticals Limited), Intas Pharmaceuticals Limited and Torrent Pharmaceuticals.
SGB Scheme 2021-22-Series VIII: Gold bond subscription will open on November 29, issue price will be Rs 4,791 / gram
MSME companies will get 50-50 crore rupees
Group B companies that will benefit from this include Biocon Limited, MSN Laboratories Private Limited, Wockhardt Limited, Alembic Pharmaceuticals Limited, Emcure Pharma, McLeods, Biological E and Natco Limited. A major part of the fund of Rs 11000 crore will go to 11 big companies of Group A. Group B companies will get an incentive of Rs 2250 crore. Each of these companies can get an incentive of Rs 250 crore. There are pharma MSMEs in Group C. Among them, 35 companies will get Rs 1750 crore. That is, 50 crore rupees to each company. In June 2021, the Center had decided to give incentives for the domestic pharma sector under the second scheme of PLI. This scheme will continue from 2020-21 to 2028-29.
Get Business News ,, latest India News ,, and other breaking news on share market, investment scheme and much more on Business Khabar. Like us on Facebook, Follow us on Twitter for latest financial news and share market updates.
.